Three Or More Saccharide Radicals (e.g., Neomycin, Etc.) Patents (Class 514/39)
-
Patent number: 7943749Abstract: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2?-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.Type: GrantFiled: April 27, 2007Date of Patent: May 17, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Michael T. Migawa, Richard H. Griffey, Eric Swayze
-
Publication number: 20110105421Abstract: Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided.Type: ApplicationFiled: March 13, 2009Publication date: May 5, 2011Applicant: The Florida International University Board of TrusteesInventors: Kalai Mathee, Allison L. Adonizio, Frederick Ausubel, Jon Clardy, Bradley Bennett, Kelsey Downum
-
Publication number: 20110076250Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Inventors: Bronislava G. Belenkaya, Vyacheslav N. Polevov, Valentina I. Sakharova, Claudia Polevov
-
Publication number: 20110046982Abstract: Disclosed herein are compounds, compositions and methods related to viral inhibition. In some forms, the compounds, compositions and methods are related to binding RNA.Type: ApplicationFiled: August 16, 2010Publication date: February 24, 2011Applicant: CLEMSON UNIVERSITY RESEARCH FOUNDATION (CURF)Inventors: Dev P. Arya, Nihar Ranjan, Sunil Kumar
-
Publication number: 20110003001Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.Type: ApplicationFiled: February 3, 2010Publication date: January 6, 2011Inventor: Brett Hugh James Baker
-
Patent number: 7858109Abstract: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin stearate, ofloxacin palmitate, ofloxacin stearate, moxifloxacin palmitate, moxifloxacin stearate, clindamycin palmitate, and clindamycin stearate. A medical device for implantation, in which the form bodies are arranged on a biodegradable filament at a distance of 1 mm to 25 mm as well as a method for the manufacture of the medical device and the use of the form bodies or the medical device to treat chronic osteomyelitis are described.Type: GrantFiled: February 15, 2007Date of Patent: December 28, 2010Assignee: Heraeus Kulzer GmbHInventors: Klaus-Dieter Kühn, Sebastian Vogt
-
Publication number: 20100298252Abstract: The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent, and an antimicrobial agent.Type: ApplicationFiled: February 18, 2010Publication date: November 25, 2010Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Branson W. Ritchie, Richard Wooley, Phillip A. Moore, William L. Weinstein
-
Patent number: 7829543Abstract: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.Type: GrantFiled: January 7, 2004Date of Patent: November 9, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Michael N. Alekshun
-
Publication number: 20100267654Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl(C1-4). In addition, processes to obtain these compounds are described.Type: ApplicationFiled: May 27, 2009Publication date: October 21, 2010Applicant: ALFA WASSERMAN, S.P.A.Inventors: Giuseppe C. VISCOMI, Manuela CAMPANA, Mahena FOLEGATTI, Paolo RIGHI, Vincenzo CANNATA, Goffredo ROSINI
-
Publication number: 20100210578Abstract: The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant allele of the filaggrin gene.Type: ApplicationFiled: January 17, 2007Publication date: August 19, 2010Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: William Henry Irwin McLean, Frances Jan Dorothy Smith
-
Publication number: 20100203100Abstract: An antimicrobial accessory may include a pressure sensitive adhesive and an antimicrobial mixed in the pressure sensitive adhesive. In some examples, an antimicrobial accessory may include at least one first domain comprising a pressure sensitive adhesive and a first antimicrobial and at least one second domain including a second polymer and a second antimicrobial. The antimicrobial accessory may be configured to be attached to a housing of an implantable medical device (IMD).Type: ApplicationFiled: February 2, 2010Publication date: August 12, 2010Applicant: Medtronic, Inc.Inventors: Kenneth E. Cobian, Genevieve L. Gallagher, Peter M. Seiler, Kiem H. Dang, Michael S. Hemenway, Zhongping Yang, James L. Schuld, Tico Blumenthal
-
Publication number: 20100196455Abstract: The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.Type: ApplicationFiled: May 2, 2008Publication date: August 5, 2010Applicant: Transave, Inc.Inventor: Vladimir Malinin
-
Patent number: 7749971Abstract: The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.Type: GrantFiled: February 20, 2002Date of Patent: July 6, 2010Inventors: David M. Bedwell, Kim M. Keeling
-
Publication number: 20100144662Abstract: The present invention relates to paromamine-based compounds according to formula I having selective antimicrobial activity directed at ribosomal 16S RNA.Type: ApplicationFiled: January 31, 2008Publication date: June 10, 2010Applicants: EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH, UNIVERSITAT ZURICH PROREKTORAT FORSCHUNGInventors: Erik C. Boettger, Andrea Vasella, Déborah Perez Fernandez
-
Publication number: 20100124554Abstract: Compounds able to affect production and/or activity of a redox active compound, which include candidate therapeutic compounds and candidate compounds for enhancing power output of a microbial fuel cell, and related compositions, methods and systems.Type: ApplicationFiled: August 26, 2009Publication date: May 20, 2010Inventors: Dianne K. Newman, Lars E.P. Dietrich, Yun Wang
-
Patent number: 7691641Abstract: The present invention relates to macromolecular polysaccharide-peptide conjugates which contain a peptide portion which C-terminally contains the amino acid sequence Ala-Gly-Arg, which is cleaved by thrombin.Type: GrantFiled: July 30, 2007Date of Patent: April 6, 2010Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Daniela Stoellner, Thilo Henckel
-
Publication number: 20100075913Abstract: A composition for inhalation which contains at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof, and an effective amount of a biofilm modifier which is a macrolide compound or a salt thereof.Type: ApplicationFiled: April 9, 2009Publication date: March 25, 2010Applicant: Galephar Pharmaceutical Research, Inc.Inventors: Arthur Deboeck, Philipee Baudier, Francis Vanderbist
-
Publication number: 20100035796Abstract: The invention relates to 17?-(5-hydroxy-C5-hydrocarbyl)-1,3,5(10)-estratrien-3,17?-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17?-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5?-esters and 3,5?-diesters thereof and to a process for the preparation thereof by reaction of 3-OR-protected estrone with an alkali metal derivative of OR-protected 5-pentynol, followed by 3-, 5-? or 3,5?-esterification.Type: ApplicationFiled: July 28, 2006Publication date: February 11, 2010Applicant: EUTICALS S.P.A.Inventors: Gillian Ashcroft, Mario Brufani, Francesca Ceccacci, Paolo Maria Farina, Luigi Filocamo, Barbara Garofalo, Roberta Joudioux, Adriana Maggi, Rinaldo Marini Bettolo, Luisa Maria Migneco
-
Patent number: 7655717Abstract: An ointment composition for treating decubitus ulcers and methods for its making and its use. The composition includes a skin protestant ointment, a rash cream, an antibiotic ointment, virgin olive oil, and boric acid powder. The skin protestant ointment includes active ingredients petroleum 53.4%, lanolin 15.5%, and inactive ingredients cod liver oil containing vitamin A & vitamin D, a fragrance, light mineral oil, microcrystalline wax, and paraffin. The rash cream includes active ingredients dimethicone 1% and zinc oxide 10%, and inactive ingredients aloe barbadensis extract, benzyl alcohol, coconut oil, cod liver oil containing vitamin A & vitamin D, a fragrance, glycerol oleate, light mineral oil, ozokerite, paraffin, propylene glycol, sorbitol, synthetic beeswax, and water. The antibiotic ointment includes active ingredients polymyxin B sulfate 5,000 units, bacitracin zinc 400 units, and neomycin base (as sulfate) 3.5 mg., and an inactive ingredient white petroleum.Type: GrantFiled: July 17, 2002Date of Patent: February 2, 2010Inventor: Mary J. Goulbourne
-
Patent number: 7635685Abstract: A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences, is disclosed. The similarity enables these aminoglycosides to be highly potent and effective antibiotics, while the significant differences enable these aminoglycosides to reduce or even block antibiotic resistance. The aminoglycosides of the present invention are suitable for inhibition of antrax lethal factor, hence are suitable for use as a cure for anthrax.Type: GrantFiled: March 8, 2005Date of Patent: December 22, 2009Assignee: Technion Research & Development Foundation Ltd.Inventors: Timor Baasov, Micha Fridman, Valery Belakhov, Sima Yaron
-
Patent number: 7612045Abstract: The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: November 3, 2009Assignee: Sequoia Sciences, Inc.Inventor: Gary R. Eldridge
-
Publication number: 20080293649Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.Type: ApplicationFiled: May 30, 2008Publication date: November 27, 2008Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
-
Patent number: 7404964Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.Type: GrantFiled: March 25, 2005Date of Patent: July 29, 2008Assignee: Idexx LaboratoriesInventors: Yerramilli V.S.N. Murthy, Robert H. Suva
-
Patent number: 7368102Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.Type: GrantFiled: December 19, 2002Date of Patent: May 6, 2008Assignee: Nektar TherapeuticsInventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
-
Patent number: 7345024Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.Type: GrantFiled: June 20, 2003Date of Patent: March 18, 2008Assignee: Heraeus Kulzer GmbH & Co. KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kühn
-
Patent number: 7259261Abstract: Processes for separation of enantiomers of clopidogrel, and converting one enantiomer of clopidogrel to another enantiomer of clopidogrel are provided. The enantiomers are separated by crystallizing the (S) enantiomer as camphor sulfonate salt from a hydrocarbon, or a mixture of a hydrocarbon and a co-solvent, preferably DMF:toluene. The (R) enantiomer is then racemized and recycled by reaction with a catalytic amount of a base, preferably with t-butoxide.Type: GrantFiled: October 4, 2004Date of Patent: August 21, 2007Assignee: TEVA Gyógyszergyár Zártkörűen Működő RészvénytársaságInventors: Merli Valeriano, Paola Daverio, Stefano Bianchi
-
Publication number: 20070190109Abstract: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin stearate, ofloxacin palmitate, ofloxacin stearate, moxifloxacin palmitate, moxifloxacin stearate, clindamycin palmitate, and clindamycin stearate. A medical device for implantation, in which the form bodies are arranged on a biodegradable filament at a distance of 1 mm to 25 mm as well as a method for the manufacture of the medical device and the use of the form bodies or the medical device to treat chronic osteomyelitis are described.Type: ApplicationFiled: February 15, 2007Publication date: August 16, 2007Applicant: HERAEUS KULZER GMBHInventors: KLAUS DIETER KUHN, SEBASTIAN VOGT
-
Patent number: 7244712Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.Type: GrantFiled: September 14, 2004Date of Patent: July 17, 2007Assignee: President and Fellows of Harvard CollegeInventor: Robert R. Rando
-
Patent number: 7115577Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: December 27, 2004Date of Patent: October 3, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 6946137Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer.Type: GrantFiled: April 18, 2003Date of Patent: September 20, 2005Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V. S. N. Murthy, Robert H. Suva
-
Patent number: 6914141Abstract: Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.Type: GrantFiled: November 4, 2002Date of Patent: July 5, 2005Inventor: Bernard Charles Sherman
-
Patent number: 6887487Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.Type: GrantFiled: October 18, 2002Date of Patent: May 3, 2005Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V. S. N. Murthy, Robert H. Suva
-
Patent number: 6858589Abstract: The invention provides a method of potentiating the activity of antibacterial agents that act on bacterial cell walls, comprising the step of administering to a subject an antibacterial agent and an aminoglycoside to attain a peak concentration of at least 4 mg/l of aminoglycoside and thereafter maintaining the aminoglycoside at a concentration of up to 4 mg/l for at least 1 hour. Compositions comprising an antibacterial agent and an aminoglycoside for efficacious treatment of bacterial infection are also provided.Type: GrantFiled: July 23, 2002Date of Patent: February 22, 2005Assignee: Pharmacy and Therapeutic Advisory Consultancy Pty LTDInventor: Allan Joseph McLean
-
Patent number: 6846807Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: July 25, 2003Date of Patent: January 25, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Publication number: 20040265241Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: ApplicationFiled: July 1, 2004Publication date: December 30, 2004Applicant: Chiron CorporationInventors: Robert John Speirs, Barbara Ann Shaeffler, Peter Bruce Challoner
-
Patent number: 6818625Abstract: The present invention relates to a method for increasing survival rate of cells in animal cell culture under hypoxia condition by adding antibiotics to the culture media. The method of present invention comprises a step of culturing animal cells in culture media containing antibacterial agent of quinolones, quinones, aminoglycosides or chloramphenicol at the concentration range of 0.1 to 1000 &mgr;g/ml. The invented method can be practically applied for high-density animal cell culture to produce recombinant proteins or cultured cells.Type: GrantFiled: July 12, 2002Date of Patent: November 16, 2004Assignee: Hypoxi Co., Ltd.Inventors: Jongwon Lee, Kyu-Won Kim, Mee-Jung Han, Moo Hwan Cho, Yang-Il Kim
-
Publication number: 20040131555Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: ApplicationFiled: December 22, 2003Publication date: July 8, 2004Applicant: Chiron CorporationInventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner
-
Patent number: 6737411Abstract: Processes for separation of enantiomers of clopidogrel, and converting one enantiomer of clopidogrel to another enantiomer of clopidogrel are provided. The enantiomers are separated by crystallizing the (S) enantiomer as camphor sulfonate salt from a hydrocarbon, or a mixture of a hydrocarbon and a co-solvent, preferably DMF:toluene. The (R) enantiomer is then racemized and recycled by reaction with a catalytic amount of a base, preferably with t-butoxide.Type: GrantFiled: November 22, 2002Date of Patent: May 18, 2004Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Merli Valeriano, Paola Daverio, Stefano Bianchi
-
Publication number: 20040067253Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.Type: ApplicationFiled: June 20, 2003Publication date: April 8, 2004Applicant: Heraeus Kulzer GmbH & Co. KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
-
Patent number: 6716822Abstract: The present invention relates to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition. The therapeutic agent of the present invention comprises antibacterial agents of quinolones, quinones, aminoglycosides or chloramphenicol as an active ingredient. Since the invented therapeutic agent improved the viability of cells under hypoxic and hypoglycemic condition, it can be clinically for ischemic diseases such as applied as a potential drug for ischemia-associated infarction and cerebral infarction.Type: GrantFiled: July 12, 2002Date of Patent: April 6, 2004Assignee: Hypoxi Co., Ltd.Inventors: Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
-
Patent number: 6706290Abstract: Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.Type: GrantFiled: July 2, 1999Date of Patent: March 16, 2004Inventors: Olvai E. Kajander, Neva Ciftcioglu
-
Publication number: 20040043947Abstract: The invention is directed to a topical composition containing neomycin, polymyxin and hydrocortisone for treating difficulty healing wounds or ulcers of the foot, ankle and lower extremity of the leg, and more particularly treating wounds and ulcers of diabetic patients.Type: ApplicationFiled: August 29, 2002Publication date: March 4, 2004Inventor: Steven A. Gersh
-
Publication number: 20040037895Abstract: The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application and ease of use. The compounds can be used in pharmaceutical compositions for the treatment of involuntary muscle spasms and in cosmetic compositions for the treatment of facial wrinkles. Also provided are kits useful for therapeutic and/or cosmetic applications.Type: ApplicationFiled: February 12, 2003Publication date: February 26, 2004Inventor: Alex Zhu
-
Publication number: 20040023899Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer.Type: ApplicationFiled: April 18, 2003Publication date: February 5, 2004Inventors: Yerramilli V.S.N. Murthy, Robert H. Suva
-
Patent number: 6664233Abstract: A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antibiotic agent such as bleomycin.Type: GrantFiled: November 10, 2000Date of Patent: December 16, 2003Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6645508Abstract: A stable composition including a water-sensitive pharmacologically active agent, such as an enzyme, an antibiotic or a vitamin, a hydrophilic non-polar primary solvent, an optional hydrophilic non-polar secondary solvent and optional pharmaceutical or cosmetic adjuvants to enhance appearance for topical use. Where the water-sensitive or water-degradable component is L-Ascorbic acid and the principal solvent is N-methyl-2-pyrrolidone (“NMP”) the composition is stable for many months at a concentration of L-Ascorbic acid of up to about 40 % w/v. This composition using NMP as a solvent and enhancer of skin penetration together with appropriate adjuvants is useful for preparing dermatological topical dosage for cosmetic and therapeutic purposes.Type: GrantFiled: June 18, 1999Date of Patent: November 11, 2003Inventor: Jivn-Ren Chen
-
Patent number: 6642365Abstract: Conjugates of a saccharide and an acetamidino- or guanidino-compound, of the formula: wherein A is CH3 or NH2; X is a linear or branched C1-C8 alkyl chain optionally containing hydroxy, amino and/or oxo groups; n is an integer from 1 to 6, and Sac is the residue of a mono-or oligo-saccharide, provided that when A is NH2 and X is -(CH2)3—CH(NH2)—C(=O)-, the monosaccharide residue is not substituted at the position 1, and n is an integer from 2 to 6 when Sac is the residue of an oligosaccharide, are useful as antiviral, particularly as antiretroviral, agents, and can be used either alone or together with other compounds used in AIDS treatment such as AZT and/or protease inhibitors, for the treatment of HIV-infection, AIDS and manifestations of AIDS such as Kaposi sarcoma.Type: GrantFiled: June 28, 2001Date of Patent: November 4, 2003Assignee: Yeda Research and Development Co. Ltd.Inventors: Aviva Lapidot, Alexander Litovchick, Artem G. Evdokimov
-
Publication number: 20030170643Abstract: The present invention involves a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to regulate plasma levels of apoB to treat cardiovascular or metabolic disorders or syndromes, a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to screen for drugs to treat cardiovascular or metabolic disorders or syndromes, and a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to screen for genes for diagnosing cardiovascular or metabolic disorders or syndromes.Type: ApplicationFiled: March 18, 2002Publication date: September 11, 2003Inventors: Edward Fisher, Kevin Jon Williams
-
Publication number: 20030143162Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: ApplicationFiled: May 17, 2002Publication date: July 31, 2003Inventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner